NCT07276958

A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

A Phase 1, Multicenter, Randomized, Placebo-Controlled, Participant-Blind, Single-Ascending Dose Study of LY4298445 in Healthy Participants and an Open-Label Single-Ascending Dose and Multiple-Ascending Dose Study of LY4298445 in Participants With Systemic Lupus Erythematosus or Rheumatoid Arthritis

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 63 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate the safety and tolerability of LY4298445 in healthy participants and in participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). Participation in the study will last up to approximately 52 weeks.

Conditions

• Healthy
• Systemic Lupus Erythematosus
• Rheumatoid Arthritis

Interventions

Type	Name	Description
DRUG	LY4298445	Administered SC
DRUG	LY4298445	Administered IV

Timeline

• Start date: 2026-02-04
• Primary completion: 2028-03-01
• Completion: 2028-03-01
• First posted: 2025-12-11
• Last updated: 2026-04-17

Locations

7 sites across 2 countries: Australia, China